Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Liang, Wenhua ^a   Wu, Xuan ^a   Fang, Wenfeng ^a   Zhao, Yuanyuan ^a   Yang, Yunpeng ^a   Hu, Zhihuang ^a   Xue, Cong ^a   Zhang, Jing ^a   Zhang, Jianwei ^a   Ma, Yuxiang ^a   Zhou, Ting ^a   Yan, Yue ^a   Hou, Xue ^a   Qin, Tao ^a   Dinglin, Xiaoxiao ^a   Tian, Ying ^a   Huang, Peiyu ^a   Huang, Yan ^a   Zhao, Hongyun ^a   Zhang, Li ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; ICOTINIB; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; CROWN ETHER; EGFR PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ADVANCED CANCER; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; COMPARATIVE EFFECTIVENESS; DIARRHEA; DRUG EFFICACY; EGFR GENE; GENE MUTATION; HUMAN; LUNG NON SMALL CELL CANCER; META ANALYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; SENSITIVITY ANALYSIS; SURVIVAL RATE; SURVIVAL TIME; BAYES THEOREM; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE FREE SURVIVAL; GENETICS; INFORMATION PROCESSING; LUNG NEOPLASMS; MUTATION; PROBABILITY; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BAYES THEOREM; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS, PHASE III AS TOPIC; CROWN ETHERS; DATA COLLECTION; DISEASE-FREE SURVIVAL; HUMANS; LUNG NEOPLASMS; MARKOV CHAINS; MUTATION; PROBABILITY; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 84895765218     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0085245     Document Type: Article

References (44)

1. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60:277-300.
2. Ramalingam S, Belani C (2008) Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions.Oncologist 13(Suppl. 1):5-13
3. Herbst RS, Heymach JV, Lippman SM (2008) Lung cancer. N Engl J Med 359:1367-80.
4. Cataldo VD, Gibbons DL, Pérez-Soler R, Quintás-Cardama A (2011) Treatment of non-small-cell lung cancer with erlotinib or gefitinib. N Engl J Med Mar 10:947-55.
5. Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, et al. (2011) Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 21:2866-74.
6. Han JY, Park K, Kim SW, Lee DH, Kim HY, et al. (2012) First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol 30:1122-8.
7. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, et al. (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362:2380-8.
8. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, et al. (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11:121-8.
9. Douillard JY, Shepherd FA, Hirsh V, Mok T, Socinski MA, et al. (2010) Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol 28:744-52.
10. Maruyama R, Nishiwaki Y, Tamura T, Yamamoto N, Tsuboi M, et al. (2008) Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. J Clin Oncol 26:4244-52.
11. Zhou C, Wu YL, Chen G, Feng J, Liu XQ, et al. (2011) Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12:735-42.
12. Zhou C, Wu YL, Chen G, Feng J, Liu XQ, et al. (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13:239-46.
13. Ciuleanu T, Stelmakh L, Cicenas S, Miliauskas S, Grigorescu AC, et al. (2012) Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. Lancet Oncol 13:300-8.
14. National Comprehensive Cancer Network. (2010) NCCN Clinical Practice Guidelines in OncologyTM. Non-Small Cell Lung Cancer. V 2. Available: http://www.nccn.org/professionals/physician gls/PDF/nscl.pdf. Accessed 2010 Apr 8.
15. Shi Y, Zhang L, Liu X, Zhou C, Zhang L, et al. (2013) Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial. Lancet Oncol 14(10):953-61
16. Miller VA, Hirsh V, Cadranel J, Chen YM, Park K, et al. (2012) Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol 13:528-38.
17. Yang JC, Shih JY, Su WC, Hsia TC, Tsai CM, et al. (2012) Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncol 13:539-48.
18. Metro G, Crinò L (2011) The LUX-Lung clinical trial program of afatinib for non-small-cell lung cancer. Expert Rev Anticancer Ther 11:673-82.
19. Salanti G, Higgins JP, Ades A, Ioannidis JP (2008) Evaluation of networks of randomized trials. Stat Methods Med Res 17: 279-301.
20. Ades AE, Sculpher M, Sutton A, Abrams K, Cooper N, et al. (2006) Bayesian methods for evidence synthesis in cost-effectiveness analysis. Pharmacoeconomics 24: 1-19. (Pubitemid 43197227)
21. Hawkins N, Scott DA, Woods BS, Thatcher N (2009) No study left behind: a network meta-analysis in non-small-cell lung cancer demonstrating the importance of considering all relevant data. Value Health 12:996-1003.
22. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, et al. (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17:1-12. (Pubitemid 26120810)
23. Valkenhoef G, Tervonen T, Zwinkels T, Brock B, Hillege H (2013) ADDIS: a decision support system for evidence-based medicine. In Decision Support Systems 55:459-475.
24. Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, et al. (2009) Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 373:746-58.
25. Sequist LV, Yang JC, Yamamoto N, O'Byrne K, Hirsh V, et al. (2013) Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 20;31(27):3327-34.
26. Wu YL, Zhou C, Hu CP, Feng JF, Lu S, et al. (2013) LUX-Lung 6: A randomized, open-label, Phase III study of afatinib (A) vs gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M+) advanced adenocarcinoma of the lung. Presented in ASCO Annual Meeting 2013. Abstract 8016.
27. Grønberg BH, Bremnes RM, Fløtten O, Amundsen T, Brunsvig PF, et al. (2009) Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 27:3217-24.
28. Rodrigues-Pereira J, Kim JH, Magallanes M, Lee DH, Wang J, et al. (2011) A randomized phase 3 trial comparing pemetrexed/carboplatin and docetaxel/carboplatin as first-line treatment for advanced, nonsquamous non-small cell lung cancer. J Thorac Oncol 6:1907-14.
29. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, et al. (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26:3543-51.
30. Socinski MA, Raju RN, Stinchcombe T, Kocs DM, Couch LS, et al. (2010) Randomized, phase II trial of pemetrexed and carboplatin with or without enzastaurin versus docetaxel and carboplatin as first-line treatment of patients with stage IIIB/IV non-small cell lung cancer. J Thorac Oncol 5:1963-9.
31. Mauri D, Polyzos NP, Salanti G, Pavlidis N, Ioannidis JP (2008) Multiple-treatments meta-analysis of chemotherapy and targeted therapies in advanced breast cancer. J Natl Cancer Inst 100:1780-91.
32. Lee CK, Brown C, Gralla RJ, Hirsh V, Thongprasert S, et al. (2013) Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis. J Natl Cancer Inst 105:595-605.
33. Kim ST, Uhm JE, Lee J, Sun JM, Sohn I, et al. (2012) Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy. Lung Cancer 75:82-8.
34. Paz-Ares L, Soulières D, Melezínek I, Moecks J, Keil L, et al. (2010) Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis. J Cell Mol Med 14:51-69.
35. Bai H, Wang Z, Chen K, Zhao J, Lee JJ, et al. (2012) Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer. J Clin Oncol 30:3077-83.
36. Li M, Zhang Q, Fu P, Li P, Peng A, et al. (2012) Pemetrexed plus platinum as the first-line treatment option for advanced non-small cell lung cancer: a meta-analysis of randomized controlled trials. PLoS One 7:e37229.
37. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, et al. (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92-8. (Pubitemid 34438899)
38. Grossi F, Aita M, Defferrari C, Rosetti F, Brianti A, et al. (2009) Impact of third-generation drugs on the activity of first-line chemotherapy in advanced nonsmall cell lung cancer: a meta-analytical approach. Oncologist 14:497-510.
39. Chen G, Feng J, Zhou C, Wu YL, Liu XQ, et al. (2012) Overall survival (OS) results from OPTIMAL (CTONG0802), a phase III trial of erlotinib (E) versus carboplatin plus gemcitabine (GC) as first-line treatment for Chinese patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC). J Clin Oncol 30(suppl; abstr 7520)
40. Baselga J, Rischin D, Ranson M, Calvert H, Raymond E, et al. (2002) Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 20:4292-302. (Pubitemid 35266289)
41. Hidalgo M, Siu LL, Nemunaitis J, Rizzo J, Hammond LA, et al. (2001) Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 19:3267-79. (Pubitemid 32591445)
42. Gordon MS, Mendelson DS, Gross M, Uttenreuther-Fischer M, Ould-Kaci M, et al. (2013) A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors. Invest New Drugs 31:409-16.
43. Zhao Q, Shentu J, Xu N, Zhou J, Yang G, et al. (2011) Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors. Lung Cancer 73:195-202.
44. Katakami N, Atagi S, Goto K, Hida T, Horai T, et al. (2013) LUX-Lung 4: A Phase II Trial of Afatinib in Patients With Advanced Non-Small-Cell Lung Cancer Who Progressed During Prior Treatment With Erlotinib, Gefitinib, or Both. J Clin Oncol [Epub ahead of print]